Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Philips Healthcare
ClinicalTrials.gov Identifier:
NCT01309048
First received: March 2, 2011
Last updated: August 28, 2012
Last verified: August 2012

March 2, 2011
August 28, 2012
January 2011
June 2012   (final data collection date for primary outcome measure)
  • Reduction of Pain Score [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
    Determine the efficacy of MR-Guided HIFU in reducing pain scores related to the site treated as measured on the Brief Pain Inventory (BPI).
  • Reduction of Pain Medication [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
    Determine the efficacy of MR-Guided HIFU in reducing pain medication usage
  • Complications and Adverse Events [ Time Frame: 90 Days ] [ Designated as safety issue: Yes ]
    Document complications and adverse events as well as the number of unintended lesions that occur as a result of treatment with MR-Guided HIFU.
Same as current
Complete list of historical versions of study NCT01309048 on ClinicalTrials.gov Archive Site
  • Changes in bone density [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
    Measure changes in bone density between X-ray and CT images taken prior to and following treatment.
  • Quality of Life [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
    Measure patient quality of life using both the EORTC QLQ-BM22 and FACT-BP scales
Same as current
Not Provided
Not Provided
 
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - A Pilot Study

This study is to confirm the safety and technical of MRI guided High Intensity Focused Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases.

MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate tissue. The MRI system identifies the ultrasound path and monitors heat rise in the tissue. The goal of the study is to show treatment safety and effectiveness. MR-guided HIFU will be performed in patients who pass inclusion/exclusion criteria.

Bone metastases are common among patients with advanced cancer and have been reported in up to 85% of cancer patients at autopsy. Complications of bone metastases include pain, functional limitation, decreased quality of life, pathological fracture, spinal cord compression and cauda equina syndrome.

External beam radiotherapy is the current standard treatment for patients with painful uncomplicated bone metastases. Unfortunately up to 30 % of patients treated with radiotherapy do not respond to therapy, and 30% of responders have their pain recur at some point after treatment. Radiotherapy re-treatment is also limited by cumulative doses delivered to sensitive structures. Ablative techniques such as cryotherapy and percutaneous radiofrequency ablation are not similarly limited by cumulative effects, however, they are invasive procedures that place patients at risk of complications.

MR-guided high intensity focused ultrasound (MR-HIFU) is a non-invasive, outpatient modality being investigated for the treatment of cancer. In MR-HIFU, a specially designed transducer is used to focus a beam of ultrasound energy into a small volume at a specific target site in the body. The focused beam produces therapeutic hyperthermia in the target field but only harmlessly warms the immediately surrounding tissue. Magnetic resonance (MR) imaging is used both to focus the ultrasound beam on the target field in the bone (the metastatic lesion and adjacent periosteum containing the nerves and vasculature for the tumor) and to perform real-time thermal mapping at and around the target. The mechanism of action of pain response is thought to be thermal periosteal denervation and / or thermal ablation of the tumor mass that diminishes pressure on the surrounding tissue.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bone Metastasis
Device: Philips MR-guided HIFU system
HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
Other Names:
  • HIFU
  • Ablation
  • High Intensity Focused Ultrasound
Experimental: Patients with painful bone metastasis
Patients with bone metastasis causing pain
Intervention: Device: Philips MR-guided HIFU system
Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol. 2002 Sep;64(3):275-80.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥18 years
  • Able to give informed consent
  • Weight <140kg
  • Radiologic evidence of bone metastases from any solid tumor
  • Able to characterize pain specifically at the site of interest (target lesion)
  • Pain score related to target lesion of ≥4 on a 0-10 point scale irrespective of medications
  • Target lesion accessible for MR-HIFU procedure
  • Target lesion maximum dimension ≤8cm
  • Target lesion is uncomplicated (i.e.: no fracture / spinal cord compression / cauda equina syndrome / soft tissue component)
  • Target lesion visible by non-contrast MRI
  • Interface between bone and skin lies ≥1cm from surface
  • Able to communicate sensation during MR-HIFU treatment
  • MR-HIFU treatment date ≥2 weeks from most recent treatment of primary tumor or any chemotherapy.

Exclusion Criteria:

  • Prior radiotherapy / surgery / ablative therapy / other local therapy to target lesion.
  • Unable to characterize pain specifically at the site of interest (target lesion)
  • Pregnant / Nursing woman
  • Target lesion is complicated (i.e.: presence of one of fracture / spinal cord compression / cauda equina syndrome / soft tissue component).
  • Target lesion <1cm from nerve bundles / bladder / bowel
  • Target lesion in contact with hollow viscera
  • Target lesion located in skull, spine (excluding sacrum which is allowed) or sternum
  • Scar along proposed HIFU beam path
  • Orthopaedic implant along proposed HIFU beam path or at site of target lesion.
  • Serious cardiovascular, neurological, renal or hematological chronic disease
  • Active infection
  • Unable to tolerate required stationary position during treatment
  • Allergy to MRI contrast agent or sedation
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01309048
02082011
No
Philips Healthcare
Philips Healthcare
Not Provided
Principal Investigator: Greg Czarnota, M.D. Radiation Oncology, Sunnybrook Health Sciences Centre
Philips Healthcare
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP